Cure Ventures Fund I, L.P.
Follow-ons onlyEmerging manager
Follow-ons only: first sale May 2021, per Form D (fund age approximates vintage)
- Vintage
- 2021
- Fund size
- $350.46M (Form D)
- Stages
- Seed, Series A, Series B
- Sectors
- Biotech
- Regions
- Global
01 · Thesis
Cure Ventures Fund I is the firm's inaugural fund. It focuses on early-stage life science and biotechnology companies, mainly new therapeutics. The fund invests in seed-stage companies and intends to co-lead later Series A and B rounds.
02 · Initial check
$3.5M to $5.84M (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Louis Tartaglia, Managing Member of the General Partner
- Richard Lim, Managing Member of the General Partner
- Dave Fallace, Managing Member of the General Partner
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
Cure Ventures is focused on early-stage investments in life science and biotechnology, primarily focused in new therapeutics. The fund invests in seed-stage companies and intends to co-lead subsequent Series A and B rounds.
the closing of its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments.
https://www.curevc.com/cure-ventures-launches-with-close-of-inaugural-350-million-dollar-fund/
06 · Sources
Last verified: Oct 25, 2026